# A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.

> **NCT05361733** · PHASE1 · RECRUITING · sponsor: **Xfibra, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- Focus of the Study: Safety of XFB19

## Interventions

- **DRUG:** XFB19
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05361733
- **Lead sponsor:** Xfibra, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-17
- **Primary completion:** 2026-09-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361733, "A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05361733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*